首页> 外文期刊>Nature >Structure of the glucagon receptor in complex with a glucagon analogue
【24h】

Structure of the glucagon receptor in complex with a glucagon analogue

机译:胰高血糖素受体与胰高血糖素类似物复合物的结构

获取原文
获取原文并翻译 | 示例
       

摘要

Class B G-protein-coupled receptors (GPCRs), which consist of an extracellular domain (ECD) and a transmembrane domain (TMD), respond to secretin peptides to play a key part in hormonal homeostasis, and are important therapeutic targets for a variety of diseases(1-8). Previous work(9-11) has suggested that peptide ligands bind to class B GPCRs according to a two-domain binding model, in which the C-terminal region of the peptide targets the ECD and the N-terminal region of the peptide binds to the TMD binding pocket. Recently, three structures of class B GPCRs in complex with peptide ligands have been solved(12-14). These structures provide essential insights into peptide ligand recognition by class B GPCRs. However, owing to resolution limitations, the specific molecular interactions for peptide binding to class B GPCRs remain ambiguous. Moreover, these previously solved structures have different ECD conformations relative to the TMD, which introduces questions regarding inter-domain conformational flexibility and the changes required for receptor activation. Here we report the 3.0 angstrom-resolution crystal structure of the full-length human glucagon receptor (GCGR) in complex with a glucagon analogue and partial agonist, NNC1702. This structure provides molecular details of the interactions between GCGR and the peptide ligand. It reveals a marked change in the relative orientation between the ECD and TMD of GCGR compared to the previously solved structure of the inactive GCGR-NNC0640-mAb1 complex. Notably, the stalk region and the first extracellular loop undergo major conformational changes in secondary structure during peptide binding, forming key interactions with the peptide. We further propose a dual-binding-site trigger model for GCGR activation-which requires conformational changes of the stalk, first extracellular loop and TMD-that extends our understanding of the previously established two-domain peptide-binding model of class B GPCRs.
机译:B类G蛋白偶联受体(GPCR)由细胞外结构域(ECD)和跨膜结构域(TMD)组成,对促胰液素肽起响应,在激素稳态中起关键作用,并且是多种激素的重要治疗靶标疾病(1-8)。先前的工作(9-11)建议肽配体根据两域结合模型结合B类GPCR,其中肽的C端区域靶向ECD,而肽的N端区域结合TMD装订袋。最近,已经解决了与肽配体复合的B类GPCR的三种结构(12-14)。这些结构提供了B类GPCR对肽配体识别的基本了解。但是,由于分辨率的限制,肽与B类GPCR结合的特异性分子相互作用仍然不明确。而且,这些先前解决的结构相对于TMD具有不同的ECD构象,这引入了有关域间构象柔韧性和受体激活所需变化的问题。在这里,我们报告了与胰高血糖素类似物和部分激动剂NNC1702结合的全长人胰高血糖素受体(GCGR)的3.0埃分辨率晶体结构。该结构提供了GCGR和肽配体之间相互作用的分子细节。与先前解决的非活性GCGR-NNC0640-mAb1复合物的结构相比,它揭示了GCGR的ECD和TMD之间的相对方向发生了显着变化。值得注意的是,茎区域和第一个细胞外环在肽结合过程中的二级结构中发生了主要的构象变化,与肽形成了关键的相互作用。我们进一步提出了一个用于GCGR激活的双重结合位点触发模型-它要求茎,第一细胞外环和TMD的构象变化-扩展了我们对先前建立的B类GPCR的两结构域肽结合模型的理解。

著录项

  • 来源
    《Nature》 |2018年第7686期|106-110|共5页
  • 作者单位

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China;

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China;

    Zhengzhou Univ, Sch Basic Med Sci, Dept Pharmacol, 100 Sci Ave, Zhengzhou 450001, Henan, Peoples R China;

    Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada;

    Novo Nordisk AS, Novo Nordisk Pk, DK-2760 Malov, Denmark;

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, 189 Guo Shou Jing Rd, Shanghai 201203, Peoples R China;

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, 189 Guo Shou Jing Rd, Shanghai 201203, Peoples R China;

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, 189 Guo Shou Jing Rd, Shanghai 201203, Peoples R China;

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China;

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China;

    Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China|Chinese Acad Sci, Inst Biophys, CAS Ctr Excellence Biomacromol, Natl Ctr Prot Sci,Natl Lab Biomacromol, Beijing 100101, Peoples R China;

    Chinese Acad Sci, Inst Biophys, CAS Ctr Excellence Biomacromol, Natl Ctr Prot Sci,Natl Lab Biomacromol, Beijing 100101, Peoples R China;

    East China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, 500 Dongchuan Rd, Shanghai 200241, Peoples R China|East China Normal Univ, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China;

    Novo Nordisk AS, Novo Nordisk Pk, DK-2760 Malov, Denmark;

    Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada|Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada;

    GPCR Consortium, San Marcos, CA 92078 USA;

    ShanghaiTech Univ, iHuman Inst, 393 Hua Xia Zhong Rd, Shanghai 201210, Peoples R China|ShanghaiTech Univ, Sch Life Sci & Technol, 393 Hua Xia Zhong Rd, Shanghai 201210, Peoples R China;

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China|Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, 189 Guo Shou Jing Rd, Shanghai 201203, Peoples R China|ShanghaiTech Univ, Sch Life Sci & Technol, 393 Hua Xia Zhong Rd, Shanghai 201210, Peoples R China|Fudan Univ, Sch Pharm, 826 Zhangheng Rd, Shanghai 201203, Peoples R China;

    Novo Nordisk AS, Novo Nordisk Pk, DK-2760 Malov, Denmark;

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Drug Discovery & Design Ctr, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China;

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China|Chinese Acad Sci, CAS Ctr Excellence Biomacromol, Beijing 100101, Peoples R China;

    Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China|Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China|ShanghaiTech Univ, Sch Life Sci & Technol, 393 Hua Xia Zhong Rd, Shanghai 201210, Peoples R China|Chinese Acad Sci, CAS Ctr Excellence Biomacromol, Beijing 100101, Peoples R China;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:51:26

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号